Literature DB >> 7295436

Hazards of diazoxide in pulmonary hypertension.

J Buch, A Wennevold.   

Abstract

The use of diazoxide in the treatment of pulmonary hypertension has been advocated recently. We describe three patients who responded less favourably. The first patient had cardiac arrest (asystole) after the acute bolus dose. After recovery only a slight increase in cardiac index was seen while pulmonary vascular resistance was unchanged. The second patient developed total atrioventricular block after the acute bolus dose. Ater recovery the cardiac index was unchanged while pulmonary vascular resistance was decreased. The third patient felt ill after the acute bolus dose, and the blood pressure dropped, but no conduction abnormalities were noted. The cardiac index rose slightly and the pulmonary vascular resistance was essentially unchanged. Long term treatment with oral diazoxide could not be administered to this patient because abdominal pain and distension developed. Because we lack reliable alternative treatment, it is justifiable to try diazoxide, provided great care is taken.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7295436      PMCID: PMC482667          DOI: 10.1136/hrt.46.4.401

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  6 in total

1.  [Prolonged treatment of severe hypoglycemia with diazoxide].

Authors:  R Saric; F Moreau; G Seguin; E Cohen; M Merlet; J C Lorin
Journal:  Sem Hop       Date:  1974-05-08

2.  Diazoxide and renal function in man.

Authors:  B F Johnson
Journal:  Clin Pharmacol Ther       Date:  1971 Sep-Oct       Impact factor: 6.875

3.  Primary pulmonary hypertension: beneficial therapy with diltiazem.

Authors:  H Kambara; K Fujimoto; A Wakabayashi; C Kawai
Journal:  Am Heart J       Date:  1981-02       Impact factor: 4.749

4.  Diazoxide in primary pulmonary hypertension.

Authors:  W P Klinke; J A Gilbert
Journal:  N Engl J Med       Date:  1980-01-10       Impact factor: 91.245

5.  Treatment for primary pulmonary hypertension.

Authors:  W P Klinke
Journal:  Am Heart J       Date:  1980-10       Impact factor: 4.749

6.  Primary pulmonary hypertension: effects of nifedipine.

Authors:  F Camerini; E Alberti; S Klugmann; A Salvi
Journal:  Br Heart J       Date:  1980-09
  6 in total
  4 in total

Review 1.  Development of Pulmonary Hypertension During Treatment with Diazoxide: A Case Series and Literature Review.

Authors:  Matthew R Timlin; Alexander B Black; Heather M Delaney; Renée I Matos; Candace S Percival
Journal:  Pediatr Cardiol       Date:  2017-06-22       Impact factor: 1.655

2.  Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin).

Authors:  D K Jones; T W Higenbottam; J Wallwork
Journal:  Br Heart J       Date:  1987-03

3.  Reversibility of primary pulmonary hypertension during six years of treatment with oral diazoxide.

Authors:  N S Chan; J McLay; A C Kenmure
Journal:  Br Heart J       Date:  1987-02

4.  Vasodilator responsiveness in idiopathic pulmonary arterial hypertension: identifying a distinct phenotype with distinct physiology and distinct prognosis.

Authors:  David Langleben; Stylianos Orfanos
Journal:  Pulm Circ       Date:  2017-06-20       Impact factor: 3.017

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.